Slide Shows

As another month comes to a close, it’s time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what’s in store on the regulatory front in June.

As another month comes to an end, it’s time to take a look back at some of the regulatory news that made headlines in February and look ahead to what the month of March has in store.

As we head into February, it's time to take a look back at some of the regulatory news that made headlines in January.

As another month comes to an end, we take a look back at some of the regulatory news that dominated the headlines and look ahead to what’s in store for January.

Just when everyone thought that the worst of the Covid-19 pandemic may be behind us, the emergence of Omicron, a new coronavirus variant, is causing global concern. Detected first in South Africa earlier this month, Omicron cases have now been reported in at least 15 countries.

Let's take a look at the biotech stocks facing FDA decision in November.

The FDA has approved 39 novel drugs so far this year compared to 40 during the same period last year. A total of 53 novel drugs were approved in 2020. Let’s take a look at the biotech stocks facing FDA decision in October.

As August draws to a close, let us take a look back at some of the regulatory headlines from that eventful month and look forward to what September has in store.